Mol, L.

patient oxaliplatin cancer treatment adjuvant colon trial adjuvant chemotherapy stage chemotherapy guideline practice mosaic trial mosaic capecitabine folfox hospital regimen capox adjuvant treatment 5 fu /lv netherland study oncol erasmus mc result cycle tabernero j dose schedules ef ficacy dutch colorectal number group criteria erasmu baseline characteristics schedule signi ficantly van gils dosage eligibility survival analysis 19 hospitals disease-free survival outcome characteristic colon cancer reason downloaded colorectal cancer adjuvant therapy ficacy therapy 08/22/12 signi percentage level uorouracil fi rst quartile capecitabine monotherapy disease-free oxaliplatin use baseline erasmus university rotterdam figure iii colon cancer tabernero dfs rate capox regimen chemotherapy use van cutsem e comorbid conditions fi rst quarter dose modi fications fl uorouracil oxaliplatin-based regimens nding ficantly